Key Takeaways
Syndax Pharmaceuticals (Nasdaq: SNDX) announced four abstracts for its leukemia drug revumenib have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, including post-transplant data from 21 patients. The findings are set to be presented at the conference in Chicago, which runs from May 29 to June 2, 2026.
"Our strong presence at ASCO highlights our scientific leadership in menin inhibition and our deep commitment to advancing cancer care," Nick Botwood, Head of Research & Development and Chief Medical Officer at Syndax, said in a statement. He noted the new evidence moves the field forward, particularly in the post-transplant setting, an area of high physician interest.
The centerpiece of the announcement is an oral presentation detailing safety and efficacy from 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib as maintenance therapy following a hematopoietic stem cell transplant. According to the company, the presentation will include overall survival and relapse rates compared to a historical cohort. Additional poster presentations will characterize the drug's unique pharmacokinetic profile, highlighting its compatibility with common acid-reducing agents, and outline the designs of two pivotal phase 3 trials for newly diagnosed patients.
The presentations aim to support revumenib's use in new settings and reinforce its profile for physicians. Shares of Syndax rose 2.4% to $20.25 in after-hours trading following the announcement.
The oral presentation (Abstract #6505) on revumenib as post-transplant maintenance therapy is scheduled for Tuesday, June 2, from 9:45 a.m. to 12:45 p.m. CDT.
Three poster presentations will be held on Monday, June 1, from 9:00 a.m. to 12:00 p.m. CDT:
Revuforj is a first-in-class menin inhibitor approved by the FDA for relapsed or refractory acute leukemia with a KMT2A gene translocation and for R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation. The drug carries a boxed warning for Differentiation Syndrome, a potentially fatal side effect that occurred in 25% of patients in clinical trials, as well as for QTc prolongation, which was reported in 36% of patients.
The new data, particularly in the post-transplant setting, could significantly expand Revuforj's addressable market if it leads to broader adoption. Investors will be closely watching the full data presentation on June 2 for details on overall survival and relapse rates compared to historical controls.
This article is for informational purposes only and does not constitute investment advice.
